Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | GABRE | P78334 | 1/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257175 | 1.00 | ACHE (0.45) | ACHEDDB1CRBNKDM4CMAPT | |
| Hydrochloric Acid SCHEMBL4254987 | 0.98 | ACHE (0.47) | ACHEDDB1CRBNKDM4CMAPT | |
| SCHEMBL8184234 | 0.87 | ACHE (0.45) | ACHEMAPTKDM4E | |
| SCHEMBL13162860 | 0.83 | ACHE (0.45) | ACHE | |
| SCHEMBL4995159 | 0.83 | ACHE (0.48) | ACHEMAPTTSHRKDM4ENPC1 | |
| SCHEMBL8247480 | 0.83 | ACHE (0.51) | ACHE | |
| SCHEMBL14345575 | 0.82 | DDB1 (0.37) | DDB1CRBNKDM4CMAPTTSHR | |
| Hydrochloric Acid SCHEMBL4995154 | 0.82 | ACHE (0.50) | ACHEMAPTTSHRKDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL4048342 | 0.82 | ACHE (0.50) | ACHEMAPTTSHRKDM4EHSD17B10 | |
| SCHEMBL8252075 | 0.81 | ACHE (0.40) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-2038284-A2 | HETEROBICYLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| WO-2008063671-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2008002671-A2 | METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007139860-A2 | HETEROBICYLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139860-A2 | HETEROBICYLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | ACHE 2784/4885DDB1 1994/4885CRBN 2599/4885 |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | ACHE 664/4885DDB1 1376/4885CRBN 3068/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | ACHE 1732/4885DDB1 3225/4885CRBN 4207/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | ACHE 1565/4885DDB1 2807/4885CRBN 4263/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ACHE 1732/4885DDB1 3225/4885CRBN 4207/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | ACHE 702/4885DDB1 2402/4885CRBN 3680/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ACHE 1732/4885DDB1 3225/4885CRBN 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.